Rex Bionics PLC Notification of Interim Results (0516L)
July 01 2014 - 5:19AM
UK Regulatory
TIDMRXB
RNS Number : 0516L
Rex Bionics PLC
01 July 2014
1 July 2014
Rex Bionics plc
("Rex Bionics" or the "Company")
Notification of Interim Results
Rex Bionics plc (AIM: RXB), the developer and manufacturer of
REX products: hands-free robotic exoskeletons for use by wheelchair
users, will issue its Interim Results for the six month period
ending 31 May 2014 on Tuesday 5 August, 2014.
Jeremy Curnock Cook, Chief Executive Officer, and Peter Worrall,
Chief Financial Officer, will host an analyst briefing at 10am BST
at Consilium Strategic Communications' offices at 1 Cornhill, EC3V
3ND, where they will present the financial and operational results
followed by a Q&A session.
For further information please contact:
Rex Bionics Plc
Jeremy Curnock Cook, Chief Executive Officer
+44 (0) 781 086 6386
Peter Worrall, Chief Financial Officer
+44 (0)1428 645416
Oriel Securities Limited (NOMAD and Broker)
Juliet Thompson/Jonathan Senior
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey
Neville
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About Rex Bionics
Rex Bionics (AIM: RXB) is an AIM-listed developer and
manufacturer of REX products, hands-free robotic exoskeletons for
use by people with mobility impairments. Founded in Auckland, New
Zealand by two robotics engineers with first-hand experience of
wheelchair users and their needs, Rex Bionics focuses on products
designed to enable wheelchair users to stand and walk autonomously
without the need for crutches or supports and is the only company
to produce hands-free walking devices for wheelchair users. Rex
Bionics' marketed products: REX Rehab and REX Personal, can be used
by people with complete spinal cord injury, but also by a much
broader potential customer base, including people with multiple
sclerosis and muscular dystrophy. In May 2014, Rex Bionics joined
AIM with a fundraising of GBP10 million (gross) to scale up
production, distribution and marketing internationally, in order to
support growing demand for both REX products as well as developing
the next generation of REX devices, REX 3.
For more information please visit, www.rexbionics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORGCGDRRBGBGSB
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rex Bionics (LSE:RXB)
Historical Stock Chart
From Sep 2023 to Sep 2024